Esophageal cancer: Outcomes of surgery, neoadjuvant chemotherapy, and three-dimension conformal radiotherapy

Journal of Surgical Oncology

Volumn 87, Issue 2, 2004, Pages 68-74

  Fréchette, Éric ^a   Buck, David A ^b   Kaplan, Brian J ^a   Chung, Theodore D ^b   Shaw, James E ^d   Kachnic, Lisa A ^b,c   Neifeld, James P ^a,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Carboplatin; Conformal radiotherapy; Esophagectomy; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME; ADJUVANT THERAPY; DRUG ADMINISTRATION; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3843125351     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20094     Document Type: Article

References (32)

1. Adelstein DJ, Rice TW, Rybicki LA, et al.: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000;18:2032-2039.
2. Apinop C, Puttisak P, Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391-393.
3. Bains MS, Stojadinovic A, Minsky B, et al.: A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiovasc Surg 2002;124:270-277.
4. Bidoli P, Bajetta E, Stani SC, et al.: Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 2002;94:352-361.
5. Blanke CD, Choy H, Teng M, et al.: Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 1999;9(2 Suppl 1):43-45.
6. Blom D, Peters JH, DeMeester TR: Controversies in the current therapy of carcinoma of the esophagus. J Am Coll Surg 2002;195:241-250.
7. Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
8. Clark PI: Medical research council randomized trial of surgery with or without preoperative chemotherapy in resectable cancer of the esophagus. Ann Oncol 2000;11 (Suppl 4):4.
9. Cooper JS, Guo MD, Herskovic A, et al.: Chemoradiotherapy of locally advanced esophageal cancer. (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
10. De Vita F, Di Martino N, Orditura M, et al.: Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: A phase II study. Chest 2002;122:1302-1308.
11. Doty JR, Salazar JD, Forastiere AA, et al.: Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. Ann Thorac Surg 2002;74:227-231.
12. Dunphy FR, Dunleavy TL, Harrisson BR, et al.: Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 2001;91:940-948.
13. Esophagus. In: American Joint Committee on cancer: AJCC Cancer Staging Manual, 6th edn. New York, NY: Springer, 2002:91-98.
14. Hainsworth JD, Meluch AA, Greco FA: Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: Preliminary results of phase II trial. Semin Oncol 1997;24(6 suppl 19):S19-S38; S19-S42.
15. Jaakkimainen L, Goodwin PJ, Pater J, et al.: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990;8:1301-1309.
16. Jemal A, Murray T, Samuels A, et al.: Cancer Statistics 2003. CA Cancer J Clin 2003;53:5-26.
17. Kelsen D, Ginsberg R, Bains M, et al.: A phase II trial of paclitaxel and cisplatinum in patients with locally advanced metastatic esophageal cancer: A preliminary report. Seminars Oncol 1997;24(Suppl 19):S19-S77; S19-S81.
18. Korst RJ, Rusch VW, Venkatraman E, et al.: Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998;115:660-669.
19. Lagergren J, Bergström R, Linden A, et al.: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831
20. Le Prise E, Etienne PL, Meunier B, et al.: A randomized study of chemotherapy, radiationtherapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784.
21. Meluch AA, Hainsworth JD, Gray JR, et al.: Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: Preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999;5:84-91.
22. Nygaard K, Hagen S, Hansen HS, et al.: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma. A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1110.
23. Pera M, Cameron AJ, Trastek VF, et al.: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-513.
24. Safran H, Akerman P, Cioffi W, et al.: Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 1999;9(2 Suppl 1):53-57.
25. Safran H, Gaissert H, Akerman P, et al.: Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19:1-7.
26. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
27. Urschel JD, Vasan H, Blewett CJ: A Meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274-279.
28. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
29. Wanebo H, Chougule P, Ready N, et al.: Surgical resection is necessary to maximaze tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol 2001;8:644-650.
30. Wanebo HJ, Chougule P, Akerley WL III, et al.: Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg 1997;174:518-522.
31. Wilson KS, Lim JT: Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: Goal of cure with organ preservation. Radiother Oncol 2000;54:129-134.
32. Wrigth CD, Wain JC, Lynch TJ, et al.: Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: A phase I and II study. J Thorac Cardiovasc Surg 1997;114:811-815.